Changes in functional connectivity in people with HIV switching antiretroviral therapy

Journal of NeuroVirology - We assessed changes in functional connectivity by fMRI (functional magnetic resonance imaging) and cognitive measures in otherwise neurologically asymptomatic people with...     

Raltegravir resistance in the cerebrospinal fluid

We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.     

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age

Background:

Antiretroviral safety and efficacy and may differ in older versus younger HIV-infected patients. The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60?years) switching combination antiretroviral therapy (cART) to a raltegravir (RAL) containing regimen.

Methods:

Nineteen HIV-infected patients over 60?years of age on effective cART (HIV-RNA Results:

In HIV-infected subjects over the age of 60 (mean?±?SD age: 66?±?3.4?years, n?=?19) switching to a RAL containing regimen, we observed no safety concerns, no plasma virological rebounds, and no differences in RAL apparent oral clearance when compared to younger HIV-infected populations (mean?±?SD age: 41?±?9.2?years, n?=?38) based on population pharmacokinetic analysis. After 24?weeks of study therapy a decline in cognitive function was observed [change in (SD) global score of (0.91 (1.3), P?=?0.018].

Conclusions:

No significant changes in RAL exposure associated with age were observed.